Comment Resolutions: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
Added more current Clinically Feasible version |
||
| Line 31: | Line 31: | ||
| 2023.02.16 | | 2023.02.16 | ||
| [[Media:QIBA CTA Comments (02.16.2023).xlsx| Clinically Feasible Comment Resolutions 2023-02-16]] | | [[Media:QIBA CTA Comments (02.16.2023).xlsx| Clinically Feasible Comment Resolutions 2023-02-16]] | ||
|- | |||
|CT Atherosclerosis 2023-03-28 | |||
|Clinically Feasible | |||
|TBD | |||
|Clinically Feasible Comment Resolutions 2023-03-28 | |||
|- | |- | ||
| [[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]] | | [[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density 2020-09-04]] | ||
| Public Comment | | Public Comment | ||
| 2019.10.16 | | 2019.10.16 | ||
| [[Media:QIBA Lung Density Comments resolved.xlsx| Public Comment Resolutions 2020-09-04]] | |[[Media:QIBA Lung Density Comments resolved.xlsx| Public Comment Resolutions 2020-09-04]] | ||
|- | |- | ||
| [[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-3.pdf|CT Small Lung Nodule Screening 2018-11-18]] | |[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-3.pdf|CT Small Lung Nodule Screening 2018-11-18]] | ||
| Technical Confirmation | | Technical Confirmation | ||
| 2020.04 | | 2020.04 | ||
| '''* Resolving Feedback''' | |'''* Resolving Feedback''' | ||
|- | |- | ||
| colspan="4" align="center" style="background:#dddddd" | '''MR Profiles''' | | colspan="4" align="center" style="background:#dddddd" | '''MR Profiles''' | ||
| Line 79: | Line 84: | ||
| [[Media:QIBATechnicalConfirmationResolutions MRE.pdf| Technical Confirmation Resolutions 2022-02-14]] | | [[Media:QIBATechnicalConfirmationResolutions MRE.pdf| Technical Confirmation Resolutions 2022-02-14]] | ||
|- | |- | ||
| [[Media: | | [[Media:QIBA DWIProfile Stage3 15Dec2022 v3.pdf| MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC) 2022-12-15]] | ||
| Clinically Feasible | | Clinically Feasible | ||
| 2022.12.15 | | 2022.12.15 | ||
Revision as of 17:09, 29 March 2023
Comments received during Public Comment, Clinically Feasible (formerly Technical) Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee.
Per the QIBA Process, committees record how each collected comment was resolved and those resolutions are posted here.